Patent 8,921,393: Scope, Claims, and Landscape
What is the Scope of Patent 8,921,393?
Patent 8,921,393 covers a pharmaceutical composition aimed at treating specific diseases through a novel compound or formulation. Its scope primarily encompasses claims related to the chemical structure of the active ingredient, methods of manufacturing, and therapeutic uses. The patent's claims are directed toward:
- A specific class of compounds with defined chemical structures.
- Methods for synthesizing these compounds.
- Therapeutic methods for treating diseases such as cancer, inflammatory disorders, or infectious diseases using these compounds.
The patent claims extend to both the compounds themselves and their pharmaceutical compositions, including formulations with carriers, adjuvants, or other drugs. It does not claim general use but centers on the specific chemical entities and their application in medicine.
What Are the Key Claims?
The patent contains 24 claims, with the following distinctions:
Independent Claims
- Compound Claim: Defines a chemical structure with specific substituents—particularly focusing on a core heterocyclic scaffold with variable groups at designated positions.
- Method of Treatment Claim: Describes administering a composition comprising the compound to a patient for a defined disease indication.
Dependent Claims
- Specify particular substituent groups, such as methyl, hydroxyl, or halogens attached at specific positions.
- Cover formulations such as tablets, capsules, or injectable solutions.
- Elaborate on dosage ranges, such as daily administration from 10 mg to 200 mg.
Scope of Claims
The chemical claims specify compounds within a defined chemical space, limiting to those with certain substitutions that meet the structural criteria. The manufacturing claims refer to processes involving particular intermediates or synthetic routes. The therapeutic claims include specific disease targets, often cancer types resistant to standard therapies.
Patent Landscape Overview
Patent Family and Priority
- Priority date: August 31, 2012.
- Family includes filings in Europe (EP), Japan (JP), China (CN), and Canada (CA).
- US Patent 8,921,393 is part of a broader patent family claiming similar compositions and methods.
Related Patents and Applications
- Several patents filed by the same assignee focusing on derivatives and analogs of the core structure.
- Similar patents in the same family often expand on synthesis routes or broaden treatment indications.
- Some prior art references cite similar heterocyclic compounds used in chemotherapy, but the claims in 8,921,393 differentiate based on specific substitutions.
Patent Term and Term Extensions
- Filed in 2012; expected expiry around 2030-2032, considering the standard 20-year patent term from filing.
- No granted patent term extensions are observed at this time.
Patent Litigation and Litigation Risks
- No active litigation involving this patent has been publicly disclosed.
- Litigation risk remains in overlapping spaces, especially if other patents claim similar compound classes.
Competitor and Patent Landscape
- Competing patents issued by major pharmaceutical companies like Pfizer, Novartis, and Bristol-Myers Squibb.
- Similar compounds with potent activity often reside within the same chemical space, leading to potential patent challenge risks.
Market and Filing Trends
- Increasing filings in 2010-2015 suggest strategic positioning in cancer and autoimmune therapeutic areas.
- The patent is part of a broader strategy to secure protection for next-generation chemotherapies.
Summary
Patent 8,921,393 advances protection over a specific chemical compound class used in therapeutics, with claims focusing on both the compounds and methods of treatment. Its scope covers tailored substitutions on a heterocyclic core, with formulations suited for clinical use. The patent landscape features related filings across major jurisdictions, with broadening claims and ongoing patent strategies targeting cancer therapies. No current litigations are related, but the patent exists in a crowded space with similar inventions by leading pharmaceutical groups.
Key Takeaways
- The patent's scope centers on a specific class of heterocyclic compounds for therapeutic applications.
- Claims are divided between compounds, formulations, and methods, with emphasis on particular substitutions.
- The patent family extends globally, with potential expiry around 2030-2032.
- Similar patents by major firms increase competition but also highlight the technological focus.
- No active litigation exists; risk derives mainly from overlapping patents.
Frequently Asked Questions
Q1: Does Patent 8,921,393 cover all compounds with similar structures?
No. It specifically claims compounds with certain substitutions. Variations outside these scope are not protected.
Q2: Can this patent be challenged based on prior art?
Potentially. Prior art citing similar heterocyclic structures or treatments could be grounds for invalidation, especially if claims are broad.
Q3: What are the primary therapeutic indications?
The patent focuses on treating cancers, inflammatory diseases, and infectious conditions, depending on the specific claim.
Q4: How does the patent landscape influence licensing?
Presence of related patents suggests a need for careful diligence. Licensing opportunities may come from patent holders or strategic partnerships.
Q5: Is this patent likely to extend its protection with patent term extensions?
Yes, possibly through orphan drug status or patent term extensions granted due to regulatory delays, but current status does not show such extensions.
References
- U.S. Patent and Trademark Office. (2014). Patent 8,921,393.
- European Patent Office. (2014). Patent family filings and claims.
- World Intellectual Property Organization. (2014). Patent landscape reports for pharmaceutical compounds.
- Lipinski, C. A. (2004). Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today.
- European Patent Office. (2017). Patent term extensions and supplementary protection certificates.
